Navigation Links
Cystic Fibrosis Foundation Therapeutics Announces $58 Million CF Drug Discovery Agreement with Pfizer
Date:11/19/2012

BETHESDA, Md., Nov. 19, 2012 /PRNewswire-USNewswire/ -- Cystic Fibrosis Foundation Therapeutics Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced a major expansion of its research collaboration with Pfizer Inc. designed to discover new drugs to treat people with the most common mutation of CF, Delta F508.

Under the new six-year pre-clinical research program with Pfizer, CFFT will invest up to $58 million to speed the discovery and development of potential therapies that target the underlying cause of cystic fibrosis. The program's goal is to advance one or more drug candidates into the clinic by the end of the multiyear collaboration.

"We are excited to expand our efforts with Pfizer to accelerate the development of more therapies that treat the root cause of CF and benefit the greatest number of people with the disease," said Robert J. Beall, Ph.D., president and CEO of the CF Foundation. "Pfizer brings impressive technical and scientific expertise, along with its commitment to improving the lives of people with cystic fibrosis."

In people with the Delta F508 mutation, a defective protein called CFTR does not fold correctly and is unable to reach the cell surface, where it is needed to help maintain the proper flow of salt and fluids into the airways. As a result, thick secretions form in the airways, leading to serious lung infections and lung damage. Nearly 90 percent of people with CF have at least one copy of the Delta F508 mutation. 

The collaboration will focus on identifying therapies that help restore normal function of the defective protein. Pfizer researchers will draw on their leading expertise in developing therapies that help mutated proteins fold and route correctly within the cell.

"Innovative collaborations between industry and patient organizations are increasingly critical in expediting the translation of science into new treatments," said Jose-Carlos Gutierrez-Ramos, senior vice president of Pfizer BioTherapeutics R&D. "We look forward to continued collaboration with the CF Foundation and to applying our leading science with the goal of identifying novel therapies for the treatment of this devastating disease."

This new agreement builds on CFFT's existing collaboration with Pfizer, which began in 2010 when Pfizer acquired the biotech company FoldRx Pharmaceuticals Inc., as part of the company's expanded effort to discover and develop innovative medicines for rare diseases. The acquisition included FoldRx's CF research program in collaboration with CFFT which started in 2007. Pfizer takes a collaborative approach to rare disease development and is partnering extensively with stakeholders throughout the community to significantly improve the lives of patients.

About the Cystic Fibrosis Foundation

The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization, and nearly every CF drug available today was made possible because of Foundation support. Based in Bethesda, Md., the Foundation also supports and accredits a national care center network that has been recognized by the National Institutes of Health as a model of care for a chronic disease. The CF Foundation is a donor-supported nonprofit organization. For more information, go to www.cff.org.


'/>"/>
SOURCE Cystic Fibrosis Foundation
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savara Pharmaceuticals AeroVanc Granted U.S. Orphan Drug Designation for the Treatment of MRSA Lung Infection in Cystic Fibrosis Patients
2. FDA Advisory Committee supports use of tobramycin inhalation powder from Novartis for patients with cystic fibrosis
3. OrPro Therapeutics Receives NIH Grant Award to Advance Development of Recombinant Thioredoxin for Treatment of Cystic Fibrosis
4. Grifols Initiates Safety Study of Inhaled Alpha1-Proteinase Inhibitor (Human) Following Orphan Drug Designation for Cystic Fibrosis
5. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in the U.S. Senate
6. Statement from the Cystic Fibrosis Foundation on Passage of the EXPERRT Act in House of Representatives
7. Savara Pharmaceuticals Completes Phase I Clinical Study of AeroVanc in Cystic Fibrosis Patients
8. Top-line Data From Phase 3 Trial of Ataluren in Patients with Nonsense Mutation Cystic Fibrosis Show Promising Results
9. Insmed Incorporated Announces Lifting of Clinical Hold by U.S. Food and Drug Administration on ARIKACE® in Cystic Fibrosis Patients With Pseudomonas Lung Infections
10. Synteract and Rempex Partner in "Great Strides" Walk to Support Cystic Fibrosis Cure
11. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... -- ivWatch LLC, a medical device company focused on improving ... pleased to announce it was the Bronze Winner last ... Equipment at the 2017 Medical Design Excellence Awards (MDEAs), ... award was presented by Medical Device and Diagnostics Industry ... New York during MD&M East, the ...
(Date:6/13/2017)... 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE and ... that the U.S. Food and Drug Administration (FDA) has notified ... relating to its Zhejiang, China manufacturing ... "The successful clearance of the Warning Letter related to ... is a measure of the progress we have made in ...
(Date:6/10/2017)... , June 9, 2017  Shane K. Burchfield, DPM, is recognized ... excellence as a Podiatrist in Alabama . ... Family First Foot Care. He brings over 20 years of experience, ... management and healthcare, to his role. ... Care, PC is pleased to welcome you to his ...
Breaking Medicine Technology:
(Date:6/25/2017)... ... ... June is Men’s Health Month and the focus is on prostate cancer. Second ... U.S. and the third most common cause of cancer related death today; lung cancer remains ... be diagnosed with prostate cancer during his lifetime. Those at highest risk are ...
(Date:6/24/2017)... ... 2017 , ... The weather is heating up and the days are getting ... be aware that the summer months provide more than warmer temperatures that are perfect ... be negatively affected from direct exposure to the sun. When it comes to the ...
(Date:6/23/2017)... ... ... By scoring 100% for fiscal management and accountability, the Arthritis National Research ... Charity Navigator, validating ANRF's work as a top charity in America. , This achievement ... earns ANRF a spot on their “ 10 Charities Worth Watching ” list as ...
(Date:6/23/2017)... ... 2017 , ... Dr. Ran Y. Rubinstein , a ... offering three new minimally invasive procedures to patients who want a younger and ... Rubinstein is excited to bring microneedling, microneedling facials, and platelet rich plasma (PRP) ...
(Date:6/23/2017)... ... June 23, 2017 , ... The Aesthetic Channel has recently highlighted Dr. ... come up with a proprietary technique that he calls the AuraLyft Facelift. ... For all ages, patients can expect to look refreshed, rejuvenated, and revitalized. , ...
Breaking Medicine News(10 mins):